Tuberculosis chemotherapy : Present situation, possible solutions, and progress towards a TB-free world

Indian Journal of Medical Microbiology

Volumn 30, Issue 3, 2012, Pages 261-263

  Dutta, Noton ^a   Karakousis, Petros ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; ANTIRETROVIRUS AGENT; AZD 5847; BEDAQUILINE; CLOFAZIMINE; DELAMANID; ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; LINEZOLID; LL 3858; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; PLACEBO; PYRAZINAMIDE; RIFAMPICIN; SUTEZOLID; THIORIDAZINE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; BACTERIAL GENE; BACTERIAL STRAIN; DISEASE TRANSMISSION; DRUG DEVELOPMENT; DRUG EFFICACY; EDITORIAL; EX VIVO STUDY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN VITRO STUDY; INTRACELLULAR PATHOGEN RESISTANCE 1 GENE; LUNG GRANULOMA; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PANDEMIC; PHARMACOGENOMICS; TREATMENT DURATION; TUBERCULOSIS;

EID: 84865580656     PISSN: 02550857     EISSN: 19983646     Source Type: Journal    
DOI: 10.4103/0255-0857.99481     Document Type: Editorial

References (21)

1. Karakousis PC. Mechanisms of action and resistance of antimycobacterial agents. In: Mayers DL, editor. Antimicrobial drug resistance. Vol. 1. New York: Humana Press; 2009. p. 271-91.
2. Karakousis PC, Williams EP, Bishai WR. Altered expression of isoniazid-regulated genes in drug-treated dormant Mycobacterium tuberculosis. J Antimicrob Chemother 2008;61:323-31.
3. Kolyva AS, Karakousis PC. Old and new TB drugs: Mechanisms of action and resistance. In: Cardona PJ, editor. Understanding tuberculosis - new approaches to fi ghting against drug resistance. InTech. ISBN: 978-953-307; 2012. p. 948-56.
4. Lauzardo M, Peloquin CA. Antituberculosis therapy for 2012 and beyond. Expert Opin Pharmacother 2012;13:511-26.
5. Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X. Global tuberculosis drug development pipeline: The need and the reality. Lancet 2010;375:2100-9.
6. Cholo MC, Steel HC, Fourie PB, Germishuizen WA, Anderson R. Clofazimine: Current status and future prospects. J Antimicrob Chemother 2012;67:290-8.
7. Dutta NK, Mazumdar K, Dastidar SG, Karakousis PC, Amaral L. New patentable use of an old neuroleptic compound thioridazine to combat tuberculosis: A gene regulation perspective. Recent Pat Antiinfect Drug Discov 2011;6:128- 38.
8. Abbate E, Vescovo M, Natiello M, Cufré M, García A, Gonzalez Montaner P, et al. Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifl oxacin and thioridazine. J Antimicrob Chemother 2012;67:473-7.
9. Tasneen R, Li SY, Peloquin CA, Taylor D, Williams KN, Andries K, et al. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother 2011;55:5485-92.
10. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, et al.The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009;360:2397-405.
11. Williams K, Minkowski A, Amoabeng O, Peloquin CA, Taylor D, Andries K, et al. Sterilizing activity of novel combinations lacking fi rst- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 2012;56:3114-20.
12. Roy CJ, Sivasubramani SK, Dutta NK, Mehra S, Golden NA, Killeen S, et al. Aerosolized gentamicin reduces the burden of tuberculosis in a murine model. Antimicrob Agents Chemother 2012;56:883-6.
13. Ahmad Z, Fraig MM, Bisson GP, Nuermberger EL, Grosset JH, Karakousis PC. Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections. Antimicrob Agents Chemother 2011;55:1527-32.
14. Ahmad Z, Klinkenberg LG, Pinn ML, Fraig MM, Peloquin CA, Bishai WR, et al. Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig. J Infect Dis 2009;200:1136-43.
15. Ahmad Z, Pinn ML, Nuermberger EL, Peloquin CA, Grosset JH, Karakousis PC. The potent bactericidal activity of streptomycin in the guinea pig model of tuberculosis ceases due to the presence of persisters. J Antimicrob Chemother 2010;65:2172-5.
16. Ahmad Z, Nuermberger EL, Tasneen R, Pinn ML, Williams KN, Peloquin CA, et al. Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig. J Antimicrob Chemother 2010;65:729-34.
17. Dutta NK, Illei PB, Peloquin CA, Pinn ML, MdluliKE, Nuermberger EL, et al. Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs. Antimicrob Agents Chemother 2012;56:3726-31.
18. Rosenthal IM, Tasneen R,Peloquin CA,Zhang M, Almeida D, Mdluli KE, et al. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother 2012; 56:4331-40
19. Dorman S, Goldberg S,Feng P,Heilig C, Stout JE,Schluger NW,et al. A phase II study of a rifapentine-containing regimen for intensive phase treatment of pulmonary tuberculosis: Preliminary results for tuberculosis trials consortium study 29. Am J Respir Crit Care Med 2011;183:A6413.
20. Dutta NK, Mehra S, Didier PJ, Roy CJ, Doyle LA, Alvarez X, et al. Genetic requirements for the survival of tubercle bacilli in primates. J Infect Dis 2010;201:1743-52.
21. Dutta NK, Veeramani B, Lamichhane G, Bader J, Karakousis PC. Computational modeling of genetic requirements for Mycobacterium tuberculosis persistence in vivo and experimental validation in murine lungs. Abstract 112thGen Meet Am Soc Microbiol. San Francisco, CA: American Society for Microbiology;2012. P. U-2061.